By reducing cytokine release syndrome and neurotoxicity, prophylactic tocilizumab could facilitate safe outpatient ...

Teclistamab maintenance, given alone or in combination with lenalidomide, demonstrated “unprecedented efficacy” in multiple myeloma patients.

IVIG prophylaxis led to improvements in infection-free survival as well as progression free and overall survival in patients ...

Anita D'Souza, MD, discusses some of the potentially practice-changing data that were presented at the 2024 ASH Annual ...

(MRD) testing achieved MRD negativity in MajesTEC-5 as induction therapy and MajesTEC-4 as maintenance therapy1,2 BEERSE, BELGIUM, Dec. 08, 2024 (GLOBE NEWSWIRE) -- Janssen-Cilag International NV, a ...

Janssen-Cilag International NV, a Johnson & Johnson company, today announced new frontline data featuring TECVAYLI®▼ (teclistamab) from two investigational studies in patients with newly diagnosed ...

Patients with newly diagnosed multiple myeloma experienced robust clinical activity when treated with Tecvayli (teclistamab) ...

Johnson & Johnson (JNJ) announced new frontline data featuring TECVAYLI (teclistamab-cqyv) from two investigational studies in ...

A woman with TEMPI syndrome who had a second relapse after many years of disease control with myeloma-type therapy had a rapid response to teclistamab, a bispecific antibody targeting plasma cells.

Simcha Therapeutics (“Simcha”), a clinical-stage immunobiology company pioneering first-in-class cytokine treatments in cancer, today announced the op ...

There is a simple discount patient access scheme for teclistamab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

Johnson & Johnson (NYSE:JNJ) today announced new frontline data featuring TECVAYLI® (teclistamab-cqyv) from two investigational studies in patients with newly diagnosed multiple myeloma (NDMM) in ...